| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/1744666X.2015.1039940 |
| P8608 | Fatcat ID | release_xeef4qmec5bopfcc4rrjutszya |
| P698 | PubMed publication ID | 25936612 |
| P2093 | author name string | Ronald A Simon | |
| Jeremy D Waldram | |||
| Kristen M Dazy | |||
| P2860 | cites work | Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice | Q24600284 |
| Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes | Q24633568 | ||
| Chronic rhinosinusitis and asthma: novel understanding of the role of IgE 'above atopy' | Q26861024 | ||
| The use of nimesulide in patients with acetylsalicylic acid and nonsteroidal anti-inflammatory drug intolerance | Q28162610 | ||
| Prevalence of asthma with aspirin hypersensitivity in the adult population of Poland | Q28165446 | ||
| Outcome analysis of endoscopic sinus surgery in patients with nasal polyps and asthma | Q28165524 | ||
| Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): Involvement of chronic hyperplastic rhinosinusitis with nasal polyposis | Q28167195 | ||
| Prostaglandin, leukotriene, and lipoxin balance in chronic rhinosinusitis with and without nasal polyposis | Q28176722 | ||
| Safety of a specific COX-2 inhibitor in aspirin-induced asthma | Q28177184 | ||
| Chronic hyperplastic eosinophilic sinusitis as a predictor of aspirin-exacerbated respiratory disease | Q28182005 | ||
| Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma | Q28186319 | ||
| Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial | Q28192038 | ||
| Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma | Q28193250 | ||
| The prevalence of aspirin intolerant asthma (AIA) in Australian asthmatic patients | Q28193330 | ||
| The safety of celecoxib in patients with aspirin-sensitive asthma | Q28193684 | ||
| The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions | Q28193909 | ||
| Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis | Q28194143 | ||
| The natural history and clinical characteristics of aspirin-exacerbated respiratory disease | Q28194291 | ||
| Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease | Q28194657 | ||
| Natural history and clinical features of aspirin-exacerbated respiratory disease | Q28195561 | ||
| Aspirin desensitization in patients with AERD | Q28195567 | ||
| Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease | Q28195577 | ||
| Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib | Q28195999 | ||
| Aspirin and NSAID sensitivity | Q28199084 | ||
| Intranasal ketorolac challenge for the diagnosis of aspirin-exacerbated respiratory disease | Q28200319 | ||
| Selection of patients for aspirin desensitization treatment | Q28200629 | ||
| EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity | Q28211293 | ||
| Effect of leukotriene modifier drugs on the safety of oral aspirin challenges | Q28212449 | ||
| Medical and surgical considerations in patients with Samter's triad | Q28213207 | ||
| Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease | Q28213966 | ||
| Expression of the cysteinyl leukotriene receptors cysLT(1) and cysLT(2) in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis | Q28217469 | ||
| Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper | Q28219101 | ||
| An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease | Q28219981 | ||
| The relationship between historical aspirin-induced asthma and severity of asthma induced during oral aspirin challenges | Q28222887 | ||
| Cysteinyl leukotrienes and their receptors; emerging concepts | Q28243252 | ||
| Aspirin activation of eosinophils and mast cells: implications in the pathogenesis of aspirin-exacerbated respiratory disease | Q30384450 | ||
| Prominent role of IFN-γ in patients with aspirin-exacerbated respiratory disease | Q30410446 | ||
| Evidence for distinct histologic profile of nasal polyps with and without eosinophilia | Q30424781 | ||
| Aspirin-exacerbated respiratory disease: evaluation and management | Q30477625 | ||
| Treatment of aspirin-intolerant asthma with antileukotrienes | Q33836771 | ||
| Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma | Q33921113 | ||
| Intolerance to aspirin. Clinical studies and consideration of its pathogenesis | Q34236999 | ||
| Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature | Q34441715 | ||
| Refractory period to aspirin in a patient with aspirin-induced asthma | Q36698892 | ||
| Sinonasal outcomes after endoscopic sinus surgery in asthmatic patients with nasal polyps: a difference between aspirin-tolerant and aspirin-induced asthma? | Q37162102 | ||
| Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes | Q37240446 | ||
| Aspirin sensitivity and desensitization for asthma and sinusitis | Q37390928 | ||
| Aspirin intolerance: does desensitization alter the course of the disease? | Q37625222 | ||
| Nasal irrigation with or without drugs: the evidence | Q37964977 | ||
| Rhinosinusitis and nasal polyps in aspirin-exacerbated respiratory disease | Q38103708 | ||
| Evidence-based approach to aspirin desensitization in aspirin-exacerbated respiratory disease | Q38173911 | ||
| Long-term sinonasal outcomes of aspirin desensitization in aspirin exacerbated respiratory disease. | Q38239473 | ||
| Aspirin or other nonsteroidal inflammatory agent exacerbated asthma | Q38273573 | ||
| Upper airways in aspirin-exacerbated respiratory disease. | Q38302625 | ||
| Cross sensitivity with acetaminophen in aspirin-sensitive subjects with asthma | Q38668673 | ||
| Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients | Q42483573 | ||
| Use of intranasal ketorolac and modified oral aspirin challenge for desensitization of aspirin-exacerbated respiratory disease | Q42950579 | ||
| Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitis | Q44432091 | ||
| The clinical dilemma of "silent desensitization" in aspirin-exacerbated respiratory disease | Q45390313 | ||
| Expression of arachidonate metabolism enzymes and receptors in nasal polyps of aspirin-hypersensitive asthmatics. | Q46034358 | ||
| Rational approach to aspirin dosing during oral challenges and desensitization of patients with aspirin-exacerbated respiratory disease | Q46214374 | ||
| Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily | Q46432280 | ||
| Sinonasal outcome under aspirin desensitization following functional endoscopic sinus surgery in patients with aspirin triad | Q48243802 | ||
| Eosinophil activation and novel mediators in the aspirin-induced nasal response in AERD. | Q50891793 | ||
| Lung volume reduction surgery and airflow limitation. | Q52246812 | ||
| Salsalate cross-sensitivity in aspirin-sensitive patients with asthma. | Q52469277 | ||
| Long-term outcome analysis of endoscopic sinus surgery for chronic sinusitis. | Q53873040 | ||
| Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study | Q57257623 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | aspirin | Q18216 |
| respiratory disease | Q3286546 | ||
| P304 | page(s) | 805-817 | |
| P577 | publication date | 2015-05-02 | |
| P1433 | published in | Expert Review of Clinical Immunology | Q15733763 |
| P1476 | title | Aspirin-exacerbated respiratory disease: characteristics and management strategies | |
| P478 | volume | 11 |
| Q90440015 | A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR |
| Q39000200 | Current complications and treatment of aspirin-exacerbated respiratory disease |
| Q28069178 | Evidence and evidence gaps in therapies of nasal obstruction and rhinosinusitis |
| Q47585305 | Intranasal drug delivery devices and interventions associated with post-operative endoscopic sinus surgery |
| Q27468568 | Natural and Synthetic Neurotoxins in Our Environment: From Alzheimer’s Disease (AD) to Autism Spectrum Disorder (ASD) |
| Q40118901 | Prenatal and infant paracetamol exposure and development of asthma: the Norwegian Mother and Child Cohort Study |
| Q64110200 | Risk of acute exacerbation between acetaminophen and ibuprofen in children with asthma |
| Q92622046 | Which Factors Associated With Activated Eosinophils Contribute to the Pathogenesis of Aspirin-Exacerbated Respiratory Disease? |
Search more.